Sepset’s novel gene signature has the potential to address early sepsis management challenges in the ER. We welcome opportunities to collaborate with diagnostic companies that wish to transfer our gene signature into a clinical platform.
If you are interested in exploring investment or partnership opportunities with Sepset, please contact:
Jonathon Jafari, MBA
Chief Business Officer & Interim Chief Executive Officer